Increasing antiviral treatment through integrated hepatitis C care: A randomized multicenter trial

Contemporary Clinical Trials

Volumn 35, Issue 2, 2013, Pages 97-107

  Groessl, Erik J ^a,b   Sklar, Marisa ^b,c   Cheung, Ramsey C ^d,e   Bräu, Norbert ^f,g   Ho, Samuel B ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d VA Palo Alto Healthcare System   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brief interventions; Case management; Hepatitis C; Integrated care; Mental health; Substance use

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ALCOHOLISM; ARTICLE; CONSULTATION; CONTROLLED STUDY; DEPRESSION; FEMALE; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; INTEGRATED CARE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE PERSONNEL; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SATISFACTION; POSTTRAUMATIC STRESS DISORDER; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF REPORT; SOCIAL SUPPORT; SUBSTANCE ABUSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

BRIEF INTERVENTIONS; CASE MANAGEMENT; HEPATITIS C; INTEGRATED CARE; MENTAL HEALTH; SUBSTANCE USE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CASE MANAGEMENT; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; RISK FACTORS; STRESS DISORDERS, POST-TRAUMATIC; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; YOUNG ADULT;

EID: 84879806759     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.05.002     Document Type: Article

References (54)

1. Davis G.L., Albright J.E., Cook S.F., Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338.
2. Bruno S., Crosignani A., Maisonneuve P., Rossi S., Silini E., Mondelli M.U. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007, 46:1350-1356.
3. Backus L.I., Boothroyd D.B., Phillips B.R., Belperio P., Halloran J., Mole L.A. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9. [509-16 e1].
4. Burney T., Dusheiko G. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Rev Anti Infect Ther 2011, 9:151-160.
5. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
6. VA Center for Quality Management in Public Health. HCV Viremic Veterans in VHA Care in 2011 with First Fill or Ever Filled a VHA Outpatient Prescription for HCV Antiviral Medications for the Nation, by VISN and by Station 2012.
7. Ho S.B., Groessl E., Dollarhide A., Robinson S., Kravetz D., Dieperink E. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol 2008, 103:1810-1823.
8. NIH National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002. Hepatology 2002, 36:S3-S20.
9. Yee H.S., Currie S.L., Darling J.M., Wright T.L. Management and treatment of hepatitis C viral infection: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program office. Am J Gastroenterol 2006, 101:2360-2378.
10. Charlebois A., Lee L., Cooper E., Mason K., Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepat 2012, 19:836-842.
11. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009, 49:561-573.
12. Knott A., Dieperink E., Willenbring M.L., Heit S., Durfee J.M., Wingert M., et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006, 101:2254-2262.
13. Stein M.R., Soloway I.J., Jefferson K.S., Roose R.J., Arnsten J.H., Litwin A.H. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat 2012, 43:424-432.
14. Ambrosini P.J., Metz C., Bianchi M.D., Rabinovich H., Undie A. Concurrent validity and psychometric properties of the Beck Depression Inventory in outpatient adolescents. J Am Acad Child Adolesc Psychiatry 1991, 30:51-57.
15. Babor T.F., de la Fuente J.R., Saunders J., Grant M. The Alcohol Use Disorders Identification Test: guidelines for use in primary health care 1992, World Health Origanization, Geneva Switzerland.
16. Reinert D.F., Allen J.P. The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research. Alcohol Clin Exp Res 2002, 26:272-279.
17. Kessler R.C., Abelson J., Demler O., Escobar J.I., Gibbon M., Guyer M.E., et al. Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res 2004, 13:122-139.
18. VA Hepatitis C Resource Center Program and National Hepatitis C Program Office. Management of psychiatric and substance use disorders in patients with hepatitis C: A reference for hepatitis C care providers 2005, 1-36.
19. Prins A., Ouimette P., Kimerling R., Cameron R.P., Hugelshofer D.S., Shaw-Hegwer J., et al. The primary care PTSD screen (PC-PTSD): development and operating characteristics. Primary Care Psychiatry 2003, 9:9-14.
20. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
21. Dienstag J.L. The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36:S152-S160.
22. Soto T.A., Bell J., Pillen M.B. Literature on integrated HIV care: a review. AIDS Care 2004, 16(Suppl. 1):S43-S55.
23. Sobell L.C., Brown J., Leo G.I., Sobell M.B. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend 1996, 42:49-54.
24. Alterman A.I., Cacciola J.S., Ivey M.A., Habing B., Lynch K.G. Reliability and validity of the alcohol short index of problems and a newly constructed drug short index of problems. J Stud Alcohol Drugs 2009, 70:304-307.
25. Amodei N., Lamb R.J. Convergent and concurrent validity of the Contemplation Ladder and URICA scales. Drug Alcohol Depend 2004, 73:301-306.
26. Sobell L.C., Sobell M.B. Timeline followback User's Guide: A Calendar Method for Assessing Alcohol and Drug Use 1996, Addictions Research Foundation, Toronto.
27. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-33. [quiz 4-57].
28. Dobie D.J., Kivlahan D.R., Maynard C., Bush K.R., McFall M., Epler A.J., et al. Screening for post-traumatic stress disorder in female Veteran's Affairs patients: validation of the PTSD checklist. Gen Hosp Psychiatry 2002, 24:367-374.
29. Dearing R.L., Barrick C., Dermen K.H., Walitzer K.S. Indicators of client engagement: influences on alcohol treatment satisfaction and outcomes. Psychol Addict Behav 2005, 19:71-78.
30. Bayliss M.S., Gandek B., Bungay K.M., Sugano D., Hsu M.A., Ware J.E. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998, 7:39-55.
31. Ware J.E., Bayliss M.S., Mannocchia M., Davis G.L. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999, 30:550-555.
32. Kind P. The EuroQol instrument: an index of health-related quality of life. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, Lippincott-Raven, Philadelphia, PA. B. Spilker (Ed.).
33. Koenig H.G., Westlund R.E., George L.K., Hughes D.C., Blazer D.G., Hybels C. Abbreviating the Duke Social Support Index for use in chronically ill elderly individuals. Psychosomatics 1993, 34:61-69.
34. Borm G.F., Fransen J., Lemmens W.A. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol 2007, 60:1234-1238.
35. Uitenbroek D.G. SISA-Binomial 1997.
36. Rosner B. Hypothesis Testing: Categorical Data - Estimation of Sample Size and Power for Comparing Two Binomial Proportions in Bernard Rosner's Fundamentals of Biostatistics 2011, 381-389. Brooks/Cole, Boston, MA. 7th ed.
37. Dieperink E., Ho S.B., Heit S., Durfee J.M., Thuras P., Willenbring M.L. Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics 2010, 51:149-156.
38. Willenbring M.L., Olson D.H. A randomized trial of integrated outpatient treatment for medically ill alcoholic men. Arch Intern Med 1999, 159:1946-1952.
39. Gilbody S., Whitty P., Grimshaw J., Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA 2003, 289:3145-3151.
40. Katon W., Von Korff M., Lin E., Simon G., Walker E., Unutzer J., et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999, 56:1109-1115.
41. Hunkeler E.M., Katon W., Tang L., Williams J.W., Kroenke K., Lin E.H., et al. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. BMJ 2006, 332:259-263.
42. The VA Hepatitis C Resource Center Program and National Hepatitis C Program Office. Management of Psychiatric and Substance Use Disorders in Patients With Hepatitis C:A Reference for Hepatitis C Care Providers 2005, Veterans Health Administration. U.S. Department of Veterans Affairs.
43. Davis G.L., Alter M.J., El-Serag H., Poynard T., Jennings L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138. [513-21, 21 e1-6].
44. Sylvestre D.L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002, 67:117-123.
45. Sylvestre D.L. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005, 40(Suppl. 5):S321-S324.
46. Sylvestre D.L., Zweben J.E. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007, 18:406-410.
47. Evon D.M., Simpson K., Kixmiller S., Galanko J., Dougherty K., Golin C., et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol 2011, 106:1777-1786.
48. Pockros P.J. Interferon-free hepatitis C therapy: how close are we?. Drugs 2012, 72:1825-1831.
49. Backus L.I., Boothroyd D.B., Phillips B.R., Mole L.A. Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: The US Department of Veterans Affairs' experience. Hepatology 2010, 52:428A.
50. Groessl E.J., Liu L., Ho S.B., Kanwal F., Gifford A.L., Asch S.M. National patterns and predictors of liver biopsy use for management of hepatitis C. J Hepatol 2012, 57:252-259.
51. Wennberg J.E. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ 2002, 325:961-964.
52. Wennberg J.E. Practice variation: implications for our health care system. Manag Care 2004, 13:3-7.
53. Campbell M.K., Elbourne D.R., Altman D.G. CONSORT statement: extension to cluster randomised trials. BMJ 2004, 328:702-708.
54. Pockros P.J. Management of patients who are not candidates for protease inhibitor therapy. Gastroenterol Hepatol 2012, 8:464-466.